BioWorld

Sep. 10, 2009

Vivus Soars Over Obesity Finish Line, Jumps into Partner Race

Vivus Inc. wowed analysts and investors on Wednesday with better-than-expected data from its final two Phase III trials of obesity drug Qnexa (phentermine/topiramate CR). (BioWorld Today) Read More

Health Care Tax on Biotechs Drawing Concern from BIO

In Separate Studies, Two New Genes Tied to Hearing Loss

Targeted Genetics Gets $7M Lifeline in Genzyme Deal

CellCyte, Ex-Officers Charged with Misleading Shareholders

Clinic Roundup

Other News To Note

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 2, 2026.

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...

AND-017 increases RBC and hemoglobin in sickle cell disease

BioWorld Science

Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...